AU2017207299B2 - Inhibiting ataxia telangiectasia and RAD3-related protein (ATR) - Google Patents

Inhibiting ataxia telangiectasia and RAD3-related protein (ATR) Download PDF

Info

Publication number
AU2017207299B2
AU2017207299B2 AU2017207299A AU2017207299A AU2017207299B2 AU 2017207299 B2 AU2017207299 B2 AU 2017207299B2 AU 2017207299 A AU2017207299 A AU 2017207299A AU 2017207299 A AU2017207299 A AU 2017207299A AU 2017207299 B2 AU2017207299 B2 AU 2017207299B2
Authority
AU
Australia
Prior art keywords
cmpd
compound
mono
combo
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017207299A
Other languages
English (en)
Other versions
AU2017207299A1 (en
Inventor
Ozan ALKAN
Daryl C. Drummond
Bolin Geng
Dmitri B. Kirpotin
Alexander KOSHKARYEV
Suresh K. TIPPARAJU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Therapeutics Inc
Original Assignee
Jazz Pharmaceuticals Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Therapeutics Inc filed Critical Jazz Pharmaceuticals Therapeutics Inc
Publication of AU2017207299A1 publication Critical patent/AU2017207299A1/en
Assigned to CELATOR PHARMACEUTICALS, INC. reassignment CELATOR PHARMACEUTICALS, INC. Request for Assignment Assignors: MERRIMACK PHARMACEUTICALS, INC.
Application granted granted Critical
Publication of AU2017207299B2 publication Critical patent/AU2017207299B2/en
Priority to AU2023282309A priority Critical patent/AU2023282309B2/en
Assigned to Jazz Pharmaceuticals Therapeutics, Inc. reassignment Jazz Pharmaceuticals Therapeutics, Inc. Request to Amend Deed and Register Assignors: CELATOR PHARMACEUTICALS, INC.
Priority to AU2025279601A priority patent/AU2025279601A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2017207299A 2016-01-11 2017-01-11 Inhibiting ataxia telangiectasia and RAD3-related protein (ATR) Active AU2017207299B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023282309A AU2023282309B2 (en) 2016-01-11 2023-12-15 Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)
AU2025279601A AU2025279601A1 (en) 2016-01-11 2025-12-09 Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662277262P 2016-01-11 2016-01-11
US62/277,262 2016-01-11
US201662420258P 2016-11-10 2016-11-10
US62/420,258 2016-11-10
US201762444172P 2017-01-09 2017-01-09
US62/444,172 2017-01-09
PCT/US2017/012939 WO2017123588A1 (en) 2016-01-11 2017-01-11 Inhibiting ataxia telangiectasia and rad3-related protein (atr)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023282309A Division AU2023282309B2 (en) 2016-01-11 2023-12-15 Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)

Publications (2)

Publication Number Publication Date
AU2017207299A1 AU2017207299A1 (en) 2018-08-02
AU2017207299B2 true AU2017207299B2 (en) 2023-09-21

Family

ID=59311885

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017207299A Active AU2017207299B2 (en) 2016-01-11 2017-01-11 Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)
AU2023282309A Active AU2023282309B2 (en) 2016-01-11 2023-12-15 Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)
AU2025279601A Pending AU2025279601A1 (en) 2016-01-11 2025-12-09 Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023282309A Active AU2023282309B2 (en) 2016-01-11 2023-12-15 Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)
AU2025279601A Pending AU2025279601A1 (en) 2016-01-11 2025-12-09 Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)

Country Status (17)

Country Link
US (5) US10570119B2 (https=)
EP (3) EP3402532B1 (https=)
JP (4) JP6918829B2 (https=)
KR (2) KR102558501B1 (https=)
CN (2) CN108697811B (https=)
AU (3) AU2017207299B2 (https=)
DK (2) DK3936153T3 (https=)
ES (2) ES2997263T3 (https=)
FI (1) FI3936153T3 (https=)
HR (1) HRP20241512T1 (https=)
IL (2) IL313681A (https=)
MA (1) MA43870A (https=)
MX (1) MX2018008507A (https=)
PL (1) PL3402532T3 (https=)
PT (1) PT3936153T (https=)
SI (1) SI3936153T1 (https=)
WO (1) WO2017123588A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018008507A (es) * 2016-01-11 2019-07-04 Merrimack Pharmaceuticals Inc Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr).
TWI755629B (zh) * 2018-09-13 2022-02-21 台灣微脂體股份有限公司 含鎮靜藥物之緩釋藥物組合物及其用途
JP7477844B2 (ja) * 2018-10-17 2024-05-02 タイワン リポソーム カンパニー リミテッド 免疫調節剤を含む徐放性医薬組成物およびその使用
US20230190752A1 (en) * 2020-05-07 2023-06-22 Washington University Compositions and methods for predicting therapeutic outcome
CA3183397A1 (en) 2020-06-18 2021-12-23 Daryl C. Drummond Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof
CA3190273A1 (en) * 2020-09-14 2022-03-17 Qun Sun Formulations of cabazitaxel
AU2021360636A1 (en) 2020-10-16 2023-06-15 Shanghai De Novo Pharmatech Co., Ltd. Triheterocyclic derivative, and pharmaceutical composition and application thereof
TW202508589A (zh) * 2023-07-14 2025-03-01 美商爵士製藥股份有限公司 包含ａｔｒ抑制劑及ｐａｒｐ抑制劑之組合及其使用方法
KR20260049706A (ko) * 2023-07-14 2026-04-14 재즈 파마슈티컬스 테라퓨틱스, 인크. Atr 억제제를 포함하는 리포좀 조성물의 사용 방법

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4990610A (en) 1988-08-25 1991-02-05 Applied Analytical Industries, Inc. Method for preparing high potency sucralfate
US5043164A (en) 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
SE0203752D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
WO2004080982A1 (en) 2003-03-11 2004-09-23 Pfizer Products Inc. Pyrazine compounds as transforming growth factor (tgf) inhibitors
CA2532228C (en) 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
LT3173073T (lt) 2004-05-03 2025-01-10 Ipsen Biopharm Ltd. Liposomos, skirtos vaistų pristatymui
GB0411401D0 (en) 2004-05-21 2004-06-23 Tissuomics Ltd Penetrating radiation measurements
EP1778648A2 (en) * 2004-08-19 2007-05-02 ICOS Corporation Compounds useful for inhibiting chk1
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
PL1888550T3 (pl) 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
WO2007015632A1 (en) 2005-08-04 2007-02-08 Cgk Co., Ltd. Atm and atr inhibitor
JP5277168B2 (ja) 2006-09-05 2013-08-28 アボット・ラボラトリーズ 血小板過剰を治療するｂｃｌインヒビター
EP3494964B1 (en) 2007-05-14 2021-04-07 Konica Minolta Holdings, Inc. Liposome and method for producing liposome
CA2743134A1 (en) 2008-11-10 2010-05-14 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
JP5951994B2 (ja) 2008-12-19 2016-07-13 イマージョン コーポレーションＩｍｍｅｒｓｉｏｎ Ｃｏｒｐｏｒａｔｉｏｎ 対話型ペインティングゲーム及び関連するコントローラ
ES2921576T3 (es) * 2008-12-19 2022-08-29 Vertex Pharma Compuestos útiles como inhibidores de la quinasa ATR
US20110053923A1 (en) * 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
CA2772989A1 (en) 2009-09-10 2011-03-17 Novartis Ag Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer
CA2798760A1 (en) 2010-05-12 2011-11-17 Vertex Pharmaceuticals Incorporated 2-aminopyridine derivatives useful as inhibitors of atr kinase
EP2568984A1 (en) 2010-05-12 2013-03-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8962631B2 (en) 2010-05-12 2015-02-24 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
NZ603477A (en) 2010-05-12 2014-09-26 Vertex Pharma Compounds useful as inhibitors of atr kinase
US9062008B2 (en) 2010-05-12 2015-06-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US9334244B2 (en) 2010-05-12 2016-05-10 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
MX2013000103A (es) 2010-06-23 2013-06-13 Vertex Pharma Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
CN102485212B (zh) * 2010-12-01 2014-04-09 沈阳药科大学 苹果酸舒尼替尼脂质体及其制备方法
CN102485213A (zh) * 2010-12-01 2012-06-06 沈阳药科大学 伊立替康脂质体及其制备方法
MX2013011450A (es) 2011-04-05 2014-02-03 Vertex Pharma Compuestos de aminopirazina utiles como inhibidores de la cinasa ataxia telangiectasia mutada y rad3 relacionados (atr).
US8822469B2 (en) 2011-06-22 2014-09-02 Vertex Pharmaceuticals Incorporated Pyrrolo[2,3-B]pyrazines useful as inhibitors of ATR kinase
US9309250B2 (en) 2011-06-22 2016-04-12 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-b]pyrazines as ATR kinase inhibitors
EP2723747A1 (en) 2011-06-22 2014-04-30 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
CN108685922A (zh) 2011-09-30 2018-10-23 沃泰克斯药物股份有限公司 用atr抑制剂治疗胰腺癌和非小细胞肺癌
WO2013049720A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
US8765751B2 (en) 2011-09-30 2014-07-01 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
WO2013049722A1 (en) 2011-09-30 2013-04-04 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
CN106496173A (zh) 2011-09-30 2017-03-15 沃泰克斯药物股份有限公司 用于制备可用作atr激酶抑制剂的化合物的方法
US8841450B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846917B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8841337B2 (en) 2011-11-09 2014-09-23 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
US8846918B2 (en) 2011-11-09 2014-09-30 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
JP2015502925A (ja) * 2011-11-09 2015-01-29 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Ａｔｒキナーゼの阻害剤として有用なピラジン化合物
CN108478577A (zh) 2012-04-05 2018-09-04 沃泰克斯药物股份有限公司 可用作atr激酶抑制剂的化合物及其组合疗法
DK2904406T3 (en) 2012-10-04 2018-06-18 Vertex Pharma METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE
EP2909202A1 (en) * 2012-10-16 2015-08-26 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
US8957078B2 (en) 2013-03-15 2015-02-17 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of ATR kinase
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
SG11201610500WA (en) 2014-06-17 2017-01-27 Vertex Pharma Method for treating cancer using a combination of chk1 and atr inhibitors
WO2016004043A1 (en) * 2014-06-30 2016-01-07 Blend Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
MX2018008507A (es) * 2016-01-11 2019-07-04 Merrimack Pharmaceuticals Inc Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr).

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHARRIER ET AL.: "Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, no. 7, 2011, pages 2320-2330 *

Also Published As

Publication number Publication date
CN116211803B (zh) 2024-10-11
EP4438127A2 (en) 2024-10-02
US20190135789A1 (en) 2019-05-09
US11028076B2 (en) 2021-06-08
IL260487B2 (en) 2024-11-01
JP2021176879A (ja) 2021-11-11
JP2019505584A (ja) 2019-02-28
AU2023282309A1 (en) 2024-01-18
JP6918829B2 (ja) 2021-08-11
EP3402532A1 (en) 2018-11-21
PL3402532T3 (pl) 2022-08-22
JP2026053650A (ja) 2026-03-25
IL313681A (en) 2024-08-01
US20250333396A1 (en) 2025-10-30
ES2921008T3 (es) 2022-08-16
KR20180096787A (ko) 2018-08-29
AU2023282309B2 (en) 2025-09-18
US11787781B2 (en) 2023-10-17
DK3936153T3 (da) 2024-11-25
FI3936153T3 (fi) 2024-11-21
EP3936153A1 (en) 2022-01-12
EP3402532B1 (en) 2022-04-13
MA43870A (fr) 2021-05-26
DK3402532T3 (da) 2022-07-11
HRP20241512T1 (hr) 2025-01-03
JP2024023349A (ja) 2024-02-21
KR20230002511A (ko) 2023-01-05
US20230416236A1 (en) 2023-12-28
EP4438127A3 (en) 2024-12-25
SI3936153T1 (sl) 2025-03-31
JP7439023B2 (ja) 2024-02-27
CN108697811B (zh) 2023-04-07
CN108697811A (zh) 2018-10-23
PT3936153T (pt) 2024-11-25
US20210300905A1 (en) 2021-09-30
AU2025279601A1 (en) 2026-01-15
KR102558501B1 (ko) 2023-07-21
KR102461219B1 (ko) 2022-10-31
WO2017123588A1 (en) 2017-07-20
EP3936153B1 (en) 2024-08-21
AU2017207299A1 (en) 2018-08-02
US10570119B2 (en) 2020-02-25
EP3402532A4 (en) 2019-09-11
IL260487A (https=) 2018-09-20
MX2018008507A (es) 2019-07-04
CN116211803A (zh) 2023-06-06
US20200399247A1 (en) 2020-12-24
ES2997263T3 (en) 2025-02-14
IL260487B1 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
AU2017207299B2 (en) Inhibiting ataxia telangiectasia and RAD3-related protein (ATR)
US20230346786A1 (en) Chiral diaryl macrocycles and uses thereof
EP3402485A1 (en) Inhibiting b-cell lymphoma 2 (bcl-2) and related proteins
EP4494643A1 (en) Method for treating patient with brca-mutated cancer
CA2825680C (en) Materials and method for inhibiting replication protein a and uses thereof
AU2024317010A1 (en) Treatment of p53 gene mutation or defect negative cancer and tumor patients
HK40065701A (en) Inhibiting ataxia telangiectasia and rad3-related protein (atr)
HK40065701B (en) Inhibiting ataxia telangiectasia and rad3-related protein (atr)
EP4357340A1 (en) Salt of selective fgfr4 inhibitor, and preparation method therefor and application thereof
EA039513B1 (ru) Ингибитор атаксии-телеангиэкстазии и rad3-родственного белка (atr) и содержащие его липосомные композиции
CN121985960A (en) Treatment of patients with negative P53 gene mutation, positive KRAS gene mutation and positive BRCA mutation

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CELATOR PHARMACEUTICALS, INC.

Free format text: FORMER APPLICANT(S): MERRIMACK PHARMACEUTICALS, INC.

FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: JAZZ PHARMACEUTICALS THERAPEUTICS, INC.

Free format text: FORMER NAME(S): CELATOR PHARMACEUTICALS, INC.